European Commission’s Joint Research Centre survey on radiopharmaceuticals for therapy

The European Commission’s Joint Research Centre, on request of the Council of the European Union, has launched a study and survey to increase the insight in the current and future use of radiopharmaceuticals for therapy in Europe: https://technopolisgroup.limequery.org/642128?lang=en.

Developments in the use of radionuclides for therapy – especially in the shape of radiopharmaceuticals – are very promising. With some radiopharmaceuticals on the verge of approval, a growth in the search for novel applications is to be expected. With this growth comes an increasing concern for the sustainable supply of radionuclides for therapy – reminiscent of the concerns for the supply of Technetium-99m in the last decades. Unfortunately, there is little information available on the use of radionuclides for therapy in Europe.

Therefore, the European Commission’s Joint Research Centre, on request of the Council of the European Union, has launched a study and survey to increase the insight in the current and future use of radiopharmaceuticals in Europe. The outcomes of this study will be publicly available and shared with all survey participants.

We encourage you to take part in this study by filing out this survey – https://technopolisgroup.limequery.org/642128?lang=en.